| AVS 56th International Symposium & Exhibition | |
| Biomaterial Interfaces | Wednesday Sessions |
| Session BI+AS+BM+MS-WeM |
| Session: | Array-Based Sensors and Diagnostics: Grand Challenges |
| Presenter: | C. Wingren, Lund University, Sweden |
| Correspondent: | Click to Email |
Antibody-based microarray is a new proteomic methodology setting a novel standard for analysing complex, non-fractionated proteomes. The first generation of antibody micro- and nanoarrays has already demonstrated its potential for generating detailed protein expression profiles, or protein maps, of human body fluids in health and disease, paving the way for new discoveries within the field of disease proteomics. The process of designing highly miniaturized, high-density and high-performing antibody array set-ups have, however, proven to be challenging. In this presentation, the key technological challenges that must be resolved in a cross-disciplinary manner before true global proteome analysis can be performed using antibody array-based sensors will be presented and discussed.
In this context, we have successfully designed a set of state-of-the-art recombinant antibody array technology platforms for high-throughput proteomics. In more detail, we use human recombinant single-chain Fv (scFv) antibody fragments, microarray adapted by molecular design as probes, displaying an outstanding on-chip functionality and stability. Uniquely, the platforms allows us to target both water-soluble as well as membrane proteins in a highly multiplexed and sensitive (pM to fM range) manner in complete, i.e. non-fractionated, directly labeled complex proteomes. Platforms compatible with a wide range of proteomes, including serum, plasma, urine, cell lysates, tissue extracts, intact cells etc, have been successfully designed. In addition, the first steps towards implementing label-free sensing ( MS, MS -MS and SPRi) as well as designing self-addressable microarrays and miniaturized attovial-based nanoarrays as well as planar nanoarrays have been taken, clearly expanding the repertoire of technology platforms. The applicability of the platform(s) for differential high-content screening of clinical samples has been validated in a set of key applications within the field of oncoproteomics, autoimmunity, inflammatory diseases and allergy. The optimized antibody microarray technology platforms, as well as data from the screening analysis will be presented in context of the grand challenges the field experiences.